Investigational anti-cancer DNA therapy eases chronic osteoarthritis pain in dogs—pointing to a new non-opioid path for humans

Elenagen™, a novel DNA plasmid therapy that previously demonstrated high clinical benefit and low toxicity in cancer patients, has now shown significant promise in alleviating chronic pain demonstrating a 90% success rate. In a peer-reviewed studypublished in Frontiers in Veterinary Science(DOI: 10.3389/fvets.2025.1519881), Elenagen reduced osteoarthritis pain scores in companion dogs. Because the same pro-inflammatory cytokine loop drives osteoarthritis and other chronic pain states, the findings offer a promising translational signal for non opioid pain medicine.